Trump Administration Drives Pharmaceutical Manufacturing Reshoring Initiative as Industry Faces Supply Chain Vulnerabilities
核心洞察
The Trump administration launched executive orders in 2025 to bolster domestic pharmaceutical manufacturing capacity, including building a stockpile of active pharmaceutical ingredients (搜索) from U.S. suppliers where possible.
Industry experts warn that the U.S. leads the world in generic drug shortages due to heavy reliance on foreign suppliers, with particular vulnerabilities in antibiotic and key starting material supply chains.
Advanced manufacturing technologies and automation are emerging as critical solutions, though experts caution that quality control systems must evolve to match increased production speeds.
The Trump administration's push to reshore pharmaceutical manufacturing gained significant momentum in 2025, with industry leaders identifying supply chain resilience as the defining trend that brought manufacturing vulnerabilities into mainstream focus. President Donald Trump issued executive orders calling for a bolstered stockpile of active pharmaceutical ingredients (搜索) (APIs), with purchasing prioritized from domestic manufacturers where possible.
Critical Supply Chain Dependencies Exposed
John Murphy, CEO of the Association for Accessible Medicines (搜索) (AAM (搜索)), emphasized the urgency of addressing manufacturing capacity gaps. "We lead the world in generic drug shortages because of our problematic reimbursement system for medicines," Murphy told industry observers. "We have very little capacity to manufacture API and key starting materials here in the United States, and so we are wholly reliant on a number of trading partners."
The vulnerability is particularly acute for antibiotics (搜索), where Murphy noted the U.S. relies heavily on one or two countries to supply all critical antibiotics. Brian Doty, vice president of R&D and programs at the nonprofit API Innovation Center (搜索) (APIIC (搜索)), described key starting material supply chains as "opaque, globally concentrated and exposed to geopolitical and environmental pressures," where small disruptions can cascade into API and drug shortages.
Beyond New Construction: Modernizing Existing Infrastructure
While initiatives such as the FDA's PreCheck program focus on encouraging new U.S. production plants, experts argue that upgrading existing facilities presents equally important opportunities. "From my vantage point in R&D, it became clear that the solution is not just to build new facilities, but to modernize how we manufacture these ingredients within facilities with excess capacity so domestic producers can compete with foreign suppliers on reliability, cost and quality," Doty explained.
The approach emphasizes "widespread adoption of advanced manufacturing that will allow domestic manufacturers to match or exceed the efficiency of global competitors," according to Doty's vision for reshoring production.
Advanced Therapies Drive Manufacturing Innovation
The cell and gene therapy sector made significant strides in manufacturing capabilities during 2025. Fabian Gerlinghaus, co-founder and CEO of Cellares (搜索), identified "the defining challenge of 2025 was the industry's realization that scaling complex, labor-intensive manufacturing workflows across fragile supply chains is no longer commercially viable."
David Dismuke, chief technical officer at gene therapy manufacturer Forge Biologics (搜索), reported measurable progress: "2025 was a turning point where several long-anticipated manufacturing improvements finally translated into measurable performance gains." He cited yield-boosting additives known as enhancers, improved media for cell growth, and improved plasmid designs as key innovations boosting productivity.
Regulatory Support Accelerates Change
The FDA's Advanced Manufacturing Technologies (AMT) program began taking shape in 2025, with Gerlinghaus noting that "the speed and clarity with which U.S. regulators embraced advanced manufacturing" exceeded expectations. The AMT designation aims to streamline the regulatory process for early adopters of new technologies.
A landmark case emerged in May when a nine-month-old boy with an ultrarare disease (搜索) received a CRISPR treatment (搜索) made specifically for him. John Maslowski, president and CEO of Forge, described the Baby KJ case as demonstrating "something fundamentally new: the ability to build a therapy even when there was no roadmap."
Quality Control Challenges Ahead
Despite manufacturing advances, experts warn of emerging challenges. Gerlinghaus cautioned that the industry may be underestimating quality control challenges as manufacturing becomes more automated and high-throughput. "If manufacturing scales but QC remains manual, the supply bottleneck may simply move downstream," he noted.
Dismuke echoed this concern, stating that while the gene therapy field "has made real progress in improving productivity and recovery in manufacturing," the gains only matter if the sector can "characterize and verify product quality with equal sophistication."
Looking to 2026
As the industry enters 2026, Murphy indicated that reindustrializing parts of the U.S. economy will remain a key focus, requiring policy and legislative changes that prioritize drug supply resilience and sustainability. However, he cautioned against attempting to manufacture everything domestically, instead advocating for building reliable supply chains that enable the U.S. "to pick up the slack if one of our trading partners has an issue in supply."
For advanced therapies, Gerlinghaus predicted that "the top priority will be establishing globally standardized, automation-native manufacturing networks capable of reliably delivering advanced therapies at commercial scale." He warned that "leaders who embrace this shift will be positioned to scale therapies globally. Those relying on manual, fragmented systems will struggle to keep pace."